Hoppe CC, Inati AC, Brown C, et al. Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor. ASH 59th Annual Meeting & Exhibition, abstract 689.
Lebrikizumab en melfalan flufenamide in de sluis geplaatst
dec 2023 | Eczeem, MM